Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.26M | 5.95M | 6.48M | 6.90M | 7.25M |
| Depreciation & Amortization | 77.90K | 70.30K | 66.80K | 31.90K | 15.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.50M | 8.18M | 9.39M | 9.82M | 9.86M |
| Operating Income | -2.50M | -8.18M | -9.39M | -9.82M | -9.86M |
| Income Before Tax | -2.99M | -8.53M | -9.72M | -10.10M | -10.11M |
| Income Tax Expenses | -- | -- | -- | -78.20K | -78.20K |
| Earnings from Continuing Operations | -2.99 | -8.53 | -9.72 | -10.03 | -10.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.99M | -8.53M | -9.72M | -10.03M | -10.03M |
| EBIT | -2.50M | -8.18M | -9.39M | -9.82M | -9.86M |
| EBITDA | -2.45M | -8.13M | -9.34M | -9.79M | -9.85M |
| EPS Basic | -0.07 | -0.19 | -0.22 | -0.23 | -0.23 |
| Normalized Basic EPS | -0.04 | -0.12 | -0.14 | -0.14 | -0.15 |
| EPS Diluted | -0.07 | -0.19 | -0.22 | -0.23 | -0.23 |
| Normalized Diluted EPS | -0.04 | -0.12 | -0.14 | -0.14 | -0.15 |
| Average Basic Shares Outstanding | 181.85M | 179.75M | 178.10M | 175.81M | 170.01M |
| Average Diluted Shares Outstanding | 181.85M | 179.75M | 178.10M | 175.81M | 170.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |